vers la météo de la validation par utilisateur
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | +--------MOD_ATT:N-N--------+ | +--------------------OBJ:V-N--------------------+ | | | +-----MOD_ATT:N-N-----+ | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ +------------COMP:N-N(from)------------+ | | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +MOD_ATT:N-ADJ+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------------COMP:V-N(from)------------------------------------------------+ | +--------MOD_ATT:N-N--------+ +------------------------------------------SUBJ:V-N------------------------------------------+ | | +-----MOD_ATT:N-N-----+ | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | +-MOD_ATT:N-N-+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ | | | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-N (__SP__,Zucker) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------MOD_ATT:N-ADJ---------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +MOD_ATT:N-ADJ+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-ADJ (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-ADJ (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------------APPOS-------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ | +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +---------------------------------APPOS---------------------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/kg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +------------------------------------------SUBJ:V-N------------------------------------------+ | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +------------------------------------------SUBJ:V-N------------------------------------------+ | | +----------MOD_ATT:N-N----------+ +--------------------OBJ:V-N--------------------+ | | | | +------MOD_ATT:N-ADJ-----+ | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | | | | | +------------COMP:N-N(of)-----------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/kg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +----------MOD_ATT:N-N----------+------------------------------------------SUBJ:V-N------------------------------------------+ | | | +------MOD_ATT:N-ADJ-----+ +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | | | +--MOD_ATT:N-ADJ--+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | | | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (administration,diabetic) MOD_ATT:N-ADJ (administration,fatty) MOD_ATT:N-ADJ (administration,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ +-COMP:N-N(from)-+ +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,Zucker) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)
+---------------------------------------------------------------------COMP:V-N(In)--------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------+ | | +---------------------------------------------------SUBJ:V-N---------------------------------------------------+ | | | +--------------------OBJ:V-N--------------------+ | +-------COMP:N-N(of)-------+ | | +-MOD_ATT:N-N-+------APPOS------+ +--------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ+ +MOD_ATT:+ +MOD_A+ | +MOD_AT+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from male Zucker diabetic fatty __SP__ , oral administration of __NODE__ ( with a dosage of 150 mg/kg/day and a treatment period of 8 weeks ) decreases expression of __SP__ __NODE__ mRNA . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (Zucker,male) MOD_ATT:N-N (__SP__,diabetic) MOD_ATT:N-ADJ (__SP__,fatty) APPOS (__SP__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,8) COMP:V-N(In) (decrease,islet) COMP:V-N(from) (decrease,Zucker) SUBJ:V-N (decrease,__SP__) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__)